Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewVU 0155041
Discontinued Product
3248 has been discontinued.
View all Glutamate (Metabotropic) Group III Receptors products.
Description: Potent positive allosteric modulator of mGlu4 receptors
Chemical Name: cis-2-[[(3,5-Dichlorophenyl)amino]carbonyl]cyclohexanecarboxylic acid
Purity: ≥99% (HPLC)
Biological Activity for VU 0155041
VU 0155041 is a potent, positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50 = 798 and 693 nM at human and rat mGlu4 receptors respectively). Active in in vivo models of Parkinson's disease following i.c.v. administration. Also available as sodium salt (Cat. No. 3311).
Technical Data for VU 0155041
| M. Wt | 316.18 |
| Formula | C14H15Cl2NO3 |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 1093757-42-6 |
| PubChem ID | 90488819 |
| InChI Key | QYHQKAPECWRTME-FBVLPHPLSA-N |
| Smiles | O=[C@](NC2=CC(Cl)=CC(Cl)=C2)[C@H]1CCCC[C@H]1[C@@](O)=O.O=[C@](NC4=CC(Cl)=CC(Cl)=C4)[C@@H]3CCCC[C@@H]3C(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for VU 0155041
References for VU 0155041
References are publications that support the biological activity of the product.
Niswender et al (2008) Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol.Pharmacol. 74 1345 PMID: 18664603
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group III Receptor Modulators
Keywords: VU 0155041, VU 0155041 supplier, Potent, positive, allosteric, mGlu4, mGluR4, agonists, mGlur, Group, III, Receptors, Glutamate, Metabotropic, VU0155041, PAM, (Metabotropic), 3248, Tocris Bioscience
3 Citations for VU 0155041
Citations are publications that use Tocris products. Selected citations for VU 0155041 include:
Duvoisin et al (2011) Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges. Behav Brain Res 221 50 PMID: 21382421
Jones et al (2011) Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 ( J Med Chem 54 7639 PMID: 21966889
Williams et al (2009) Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4). Bioorg Med Chem Lett 19 4967 PMID: 19640716
Reviews for VU 0155041
There are currently no reviews for this product. Be the first to review VU 0155041 and earn rewards!
Have you used VU 0155041?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.